EP1861357B1 - Neue verbindungen oder pharmazeutisch unbedenkliche salze davon als vanilloidrezeptorantagonist, und pharmazeutische zusammensetzungen, die diese enthalten - Google Patents

Neue verbindungen oder pharmazeutisch unbedenkliche salze davon als vanilloidrezeptorantagonist, und pharmazeutische zusammensetzungen, die diese enthalten Download PDF

Info

Publication number
EP1861357B1
EP1861357B1 EP06716379.0A EP06716379A EP1861357B1 EP 1861357 B1 EP1861357 B1 EP 1861357B1 EP 06716379 A EP06716379 A EP 06716379A EP 1861357 B1 EP1861357 B1 EP 1861357B1
Authority
EP
European Patent Office
Prior art keywords
fluoro
butyl
methanesulfonylamino
phenyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP06716379.0A
Other languages
English (en)
French (fr)
Other versions
EP1861357A4 (de
EP1861357A1 (de
Inventor
Seol Rin Park
Uh Taek College of Pharmacy Seoul National University OH
Hyeung-Geun College of Pharmacy Seoul National University PARK
Young-Ger College of Pharmacy Seoul National Universty SUH
Hee-Doo c/o College of Pharmacy Sookmyung Women's Univ. KIM
Kyung Min 320-1205 SIBUM DAEUN Maeul POSCO THE SHARP LIM
Jin Kyu 126-1601 Hyundai Hometown Apt. CHOI
Hyun Ju 105-406 Dusan Apt. KOH
Jin Kwan 102-606 Daewoo Prugio Apt. 951 KIM
Ki-Wha 209-501 Sangnoksu Apt. LEE
Young-Ho Park
Mi Jung Jang
Yeon Su 118-803 Sungwon Apt. JEONG
Joo Hyun Kim
Sun-Young Kim
Song Seok Shin
Byoung Young 105-1906 ChamsolMaeul World Meridian Apt. WOO
Sung-Il 480-2 Hongjuk-ri KIM
Joo Hyun 314-1 Bora-ri MOH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Publication of EP1861357A1 publication Critical patent/EP1861357A1/de
Publication of EP1861357A4 publication Critical patent/EP1861357A4/de
Application granted granted Critical
Publication of EP1861357B1 publication Critical patent/EP1861357B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/11—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te

Definitions

  • the vanilloid receptor is highly expressed in primary afferent sensory neurons. It is also reportedly expressed in various organs and tissues such as the bladder, kidney, lungs, intestines and skin, and in the central nervous system (CNS) including the brain and non-neuronal tissues ( Mezey et al., 2000, PNAS, 97, pp3655-3660 ; Stander et al., 2004, Exp. Dermatol.
  • vanilloid receptor agonist capsaicin
  • the vanilloid receptor antagonist exerts defense actions against such damage to nerve functions and nerve cell death ( Holzer P, 1991, Pharmacological Reviews, 43, pp143-201 ; Mezey et al., 2000, PNAS, 97, 3655-3660 ).
  • the vanilloid receptor is expressed in all regions of the gastrointestinal tract, for example, ganglia of tensor, tunica muscularis, mucosa and epithelial cells. In particular, the vanilloid receptor is highly expressed in inflammatory disorders of the colon and ileum.
  • One embodiment of the present invention relates to compounds of formula I as defined further above, wherein X is CHR11-CHR12. These compounds have the general formula (Ib). wherein, R 11 and R 12 are independently hydrogen, halogen, C1-C5 alkyl, C1-C5 alkoxy, halo (C1-C5) alkyl, or phenyl; R 1 is ethenyl or ethynyl; R 2 is hydrogen, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo (C1-C5) alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxy, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl, or phenyl (C1-C3) alkyl, wherein, each phenyl may be unsubstituted or substituted with one or more substituent selected from carboxy, C
  • Example No. Structure 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 Reference Example 50 51 52 53 Reference Example 54 55 56 57 Reference Example 58 Reference Example 59 Reference Example 60
  • the above Scheme 5 shows another process for synthesizing the acrylamide compound.
  • the compound (20) is synthesized using DMTMM ⁇ 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride ⁇ ( Tetrahedron Lett., 1999, 40, 5327 ) instead of diethylcyanophosphate.
  • the Scheme 14 shows a proposed process for synthesizing urea compound having phenylacetylenyl group.
  • Iodoaniline compound is reacted with phenylacetylene via sonogashira reaction to yield compound (44).
  • the compound (44) is reacted with methanesulfonyl anhydride to yieid compound (45).
  • the compound (45) is treated with TFA to yield benzylamine compound (46).
  • Benzylamine compound (46) is reacted with phenylisocyanate to yield urea compound (47).
  • Compound (47) is reduced with lindlar catalyst to prepare urea compound (48) with phenyl ethane moiety.
  • the present invention also provides a pharmaceutical composition for preventing and treating a condition related to vanilloid receptor, where said composition comprises a compound of formula (I), (1a), (Ib), (1c) or (Id) or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier.
  • the present invention provides a pharmaceutical composition for treating a condition selected from pain, inflammatory disease of the joints including inflammatory autoimmune diseases of the joints, urinary bladder hypersensitivity including urinary incontinence, stomach duodenal ulcer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), neurotic/allergic/inflammatory skin disease, psoriasis, asthma, chronic obstructive pulmonary disease (COPD), pruritus, or prurigo comprising a compound or a pharmaceutically acceptable salt thereof according to anyone of formula (I), (1a), (Ib), (1c) or (Id), as defined further above.
  • inventive compounds can be used in a pharmaceutical composition for treating pain, wherein the pain is -or is associated with- a condition selected from osteoarthritis ("OA"), rheumatoid arthritis ("RA”), Ankylosing Spondylitis (“AS”), diabetic neuropathic pain, post-operative pain, non-inflammatory musculoskeletal pain (including fibromyalgia, myofascial pain syndrome and back pain), migraine and other types of headaches.
  • OA osteoarthritis
  • RA rheumatoid arthritis
  • AS Ankylosing Spondylitis
  • diabetic neuropathic pain post-operative pain
  • non-inflammatory musculoskeletal pain including fibromyalgia, myofascial pain syndrome and back pain
  • migraine other types of headaches.
  • the compounds according to the present invention are said to be of use in treating pain associated with an inflammatory autoimmune disease of the joints, this refers to the administration of the compounds or combinations of the compounds of the present invention to reduce at least one pain symptom experienced by a subject suffering from an inflammatory autoimmune disease of the joints including back pain, joint pain and muscle pain associated with RA or AS.
  • treatment of an inflammatory autoimmune disease of the joints may also include a decrease of the inflammation and/or swelling of the synovium and may help to improve the functionality (i.e. maintaining mobility, and minimizing disability) of the joints, in particular in patients suffering from RA or AS.
  • fibromyalgia or "FMS” relates to a syndrome that causes widespread pain and stiffness throughout the tissue that supports and moves bones and joints. Fibromyalgia can be diagnosed by the presence of excessive tenderness on applying pressure to at least 11 of 18 specific muscle-tendon sites.
  • a compound of formula (I), (1a), (Ib), (1c) or (Id) or a pharmaceutically acceptable salt thereof according to the present invention can be prepared as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants, and diluents.
  • the compounds of the present invention can be dissolved in oils, propylene glycol or other solvents which are commonly used to produce an injection. Suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils or isopropyl myristate.
  • the compounds of the present invention can be formulated in the form of ointment or cream.
  • the compound according to the present invention may also be used in the forms of pharmaceutically acceptable salts thereof, and may be used either alone or in combination or in admixture with other pharmaceutically active compounds.
  • the preferable dose level of the compounds according to the present invention depends upon a variety of factors including the condition and body weight of the patient, severity of the particular disease, dosage form, and route and period of administration, but may appropriately be chosen by those skilled in the art.
  • the compounds of the present invention are preferably administered in an amount ranging from 0.001 to 100 mg/kg of body weight per day, and more preferably from 0.01 to 30 mg/kg of body weight per day. Doses may be administered once a day, or several times a day with each divided portions.
  • the compounds of the present invention are used in a pharmaceutical composition in an amount of 0.0001 ⁇ 10% by weight, and preferably 0.001 ⁇ 1 % by weight, based on the total amount of the composition.
  • Step 5 (4-methanesulfonylamino-3-vinylbenzyl)carbamic acid t-butyl ester
  • Step 2 (3-ethynyl-5-fluoro-4-methanesulfonylaminobenzyl)carbamic acid t-butyl ester
  • step 1 (4-amino-2-chloro-5-vinylbenzyl)carbamic acid t-butyl ester
  • Step 2 (2-chloro-4-methanesulfonylamino-5-vinylbenzyl)carbamic acid t-butyl ester
  • a dried 25 ml two-neck round bottom flask was filled with argon gas and the solution of 4-t-butylbenzylamine (29.38 ⁇ l , 0.18mmol) in methylene chloride was added to the flask.
  • Boc 2 O(1.5eq, 0.27mmol, 151.78 ⁇ l ) and DMAP (0.2 eq, 0.09 mmol, 10.15 mg) slowly and stirred for 5 hours.
  • Step 4 N- ⁇ 4-[3-(4-t-butylbenzyl)ureidomethyl]-5-chloro-2-ethynyl phenyl ⁇ methanesulfonamide
  • a dried 25 ml two-neck round bottom flask was filled with argon gas and the solution of tetrakis(triphenyl phosphine)palladium(0) (27.9mg , 0.02mmol, 0.06 eq.) and lithium chloride(47.7mg, 1.13 mmol, 2.8 eq.) in DMF was put into the flask.
  • Step 4 (4-Amino-3-methyl-5-vinylbenzyl)carbamic acid tert-butyl ester
  • Step 2 (4-Amino-3-chloro-5-iodobenzyl)carbamic acid tert-butyl ester
  • N-(4-Aminomethyl-2-chloro-6-vinylphenyl)methanesulfonamide (step 5 of Ex 9, 1 eq, 33.4mg, 0.09mmol), 3-(4-tert-butylphenyl)acrylic acid (1.2eq, 0.11 mmol, 21.87mg), DEPC (1.2eq, 0.11 mmol, 16.63 ⁇ l), and TEA (2eq, 0.18mmol, 25.09 ⁇ l) were added in DMF. The mixture was stirred for 12hr. The reaction mixture was purified according to Example17 to give a white solid (20.8mg, 51.80%).
  • N-(4-Aminomethyl-2-trifluoromethyl-6-vinylphenyl)methanesulfonamide (step 7 in Example 10, 1eq, 44.1mg, 0.13mmol), 3-(4-tert-Butyl-phenyl)-acrylic acid (1.1eq, 0.15mmol, 29.99mg), DEPC(1.2eq, 0.16mmol, 23.67 ⁇ l) and TEA(2eq, 0.26mmol, 36.24 ⁇ l) were added in DMF. The reaction mixture was stirred for 12hr. The reaction mixture was purified according to Example 17 to give a white solid (55.4mg, 88.75%).
  • Step 1 3-[4-tert-Butyl-2-(2-piperidine-1-yl-ethoxy)phenyl] acrylic acid ethyl ester
  • Step 3 3-(4-tert-Butyl-2-hydroxyphenyl)-N-(3-fluoro-4-methanesulfonylamino-5-vinylbenzyl)acrylamide
  • Step 1 3-(4-tert-Butyl-2-trifluoromethanesulfonyloxyphenyl) acrylic acid ethyl ester
  • Step 1 3-[4-tert-Butyl-2-(tetrahydropyran-4-yloxy)-phenyl]acrylic acid methyl ester
  • Step 2 3-[4-tert-Butyl-2-(tetrahydropyran-4-yloxy)phenyl]-N-(3-fluoro-4-methanesulfonylamino-5-vinylbenzyl)acrylamide
  • Step 1 3-[4-tert-Butyl-2-(tetrahydropyran-4-yloxy)phenyl]propionic acid methyl ester
  • N-(4-aminomethyl-2-fluoro-6-vinylphenyl)methanesulfonamide (0.10mmol, 35.0mg)
  • 3-(4-tert-butylphenyl)-2-methylpropionic acid (0.11mmol, 23.65mg)
  • DEPC DEPC(0.12mmol, 18.21 ⁇ l)
  • TEA TEA(0.20mmol, 27.88 ⁇ l)
  • Step 3 3-[4-(tert-butyl)phenyl]-N-[4- (methanesulfonylamino)-3-vinyl benzyl]propionamide
  • Step 1 (4-Amino-2-methoxy-benzyl)-carbamic acid tert-butyl ester
  • Step 3 (4-Amino-2-methoxy-5-vinyl-benzyl)-carbamic acid tert-butyl ester
  • Step 5 N- ⁇ 4-[3-(4-tert-Butyl-benzyl)-ureidomethyl]-5-methoxy-2-vinyl-phenyl ⁇ -methanesulfonamide
  • Step 3 1-(4-amino-3-fluoro-5-vinyl-benzyl)-3-(4-t-butyl-benzyl)-urea
  • Step 1 3-(4-tert-Butyl-phenyl)-2-phenyl-acrylic acid
  • Phenyl acetic acid (489 mg, 3.59 mmol) and 4-t-butylbenzaldehyde (573 mmg, 3.53 mmol), TEA (5ml) and acetic anhydride (5ml) were added in round flask. A reaction mixture was heated and stirred overnight. The reaction mixture was poured into 5% HCl aqueous solution (30 ml). A aqueous solution was extracted with MC (30 ml x 3). A combined organic layer was dried over MgSO 4 and then concentrated in vacuo.
  • Step 2 3-(4-tert-butyl-phenyl)-N-(4-methanesulfonylamino-3-vinyl-benzyl)-2-phenyl-acrylamide
  • N-[4-(1-Aminoethyl)-2-vinylphenyl]methanesulfonamide (236.7mg, 0.985mmol, 1eq.) and Triethylamine (274.6 ⁇ l, 1.970mmol, 2eq.) were added in methylene chloride.
  • the reaction mixture was cooled down to 0°C.
  • 4-tert-Butylphenyl isocyanate (192.5 ⁇ l, 1.083mmol, 1.3eq.) was added.
  • the reaction mixture was stirred for 40 min. Methylene chloride was removed in vacuo.
  • Step 2 (R)- [1-(4-Methanesulfonylamino-3-trimethylsilanylethynyl phenyl)ethyl]carbamic acid tert-butyl ester
  • N-[4-(1-Amino-ethyl)-2-vinyl-phenyl]-methanesulfonamide (236.7 mg, 0.985 mmol) and triethylamine (274.6 ⁇ l, 1.970 mmol, 2eq) were added in methylene chloride.
  • the reaction mixture was cooled down to 0°C.
  • 4-tert-Butylphenyl isocyanate (192.5 ⁇ l, 1.083mmol, 1.3eq.) was added into the mixture.
  • the reaction mixture was stirred for 40 min. A reaction solvent was removed in vacuo.
  • N-(4-Aminomethyl-2-fluoro-6-vinylphenyl)methanesulfonamide 37.8 mg, 0.11 mmol
  • 1-tert-butyl-4-isocyanatobenzene 1.2eq, 0.13mmol, 22.49 ⁇ l
  • TEA TEA(3eq, 0.33mmol, 45.99 ⁇ l)
  • Step 1 [1-(4-Amino-3-phenylethynylphenyl)ethyl]carbamic acid tert-butyl ester
  • Step 2 [1-(4-Methanesulfonylamino-3-phenylethynylphenyl)ethyl]carbamic acid tert-butyl ester
  • Step 3 N-(4- ⁇ 1-[3-(4-tert-Butylphenyl)ureido]ethyl ⁇ -2-phenylethynylphenyl)methanesulfonamide
  • N-[4-(1-Aminoethyl)-2-phenylethynylphenyl]methanesulfonamide 440.1 mg, 1.40 mmol
  • TEA 390.3 ⁇ l, 2.800mmol, 2eq
  • the reaction mixture was cooled down to 0°C.
  • 4-tert-Butylphenyl isocyanate (248.8 ⁇ l, 1.540mmol, 1.3eq.) was added into the mixture.
  • the reaction mixture was stirred for 1 hr. Methylene chloride was removed in vacuo.
  • Neonatal(2-3 day old or younger than 2-3 day old) SD rats were put in ice for 5 minutes to anesthetize and disinfected with 70% ethanol.
  • DRG of all part of spinal cord were dissected (Wood et al., 1988, J. Neurosci. 8, pp3208-3220) and collected in DME/F12 medium to which 1.2g/l sodium bicarbonate, 50mg/l gentamycin were added. The DRG were incubated sequentially at 37°C for 30 min in 200 U/ml collagenase and 2.5mg/ml trypsin, separately.
  • the ganglia were washed twice with DME/F12 medium supplemented with 10% horse serum, triturated through a fire-polished Pasteur pipette, filtered through Nitex 80 membrane to obtain single cell suspension and the suspension was washed once more. This was subjected to centrifugation, then resuspended in cell culture medium at certain level of cell density.
  • DME/F12 medium supplemented with 10% horse serum was diluted with identical medium conditioned by C6 glioma cells 2 days on a confluent monolayer (1:1), and NGF (Nerve Growth Factor) was added to adjust 200ng/ml as final concentration.
  • DRG nerve cells from the primary culture of 2 days were equilibrated by washing 4 times with HEPES (10mM, pH 7.4)-buffered Ca 2+ , Mg 2+ -free HBSS (H-HBSS).
  • HEPES HEPES
  • the solution in each well was removed from the individual well.
  • Medium containing the test compound plus capsaicin (final concentration 0.5 ⁇ M) and 45 Ca (final concentration 10 ⁇ Ci/ml) in H-HBSS was added to each well and incubated at room temperature for 10 mins. Terasaki plates were washed five times with H-HBSS and dried at room temperature. To each well, 0.3% SDS (10 ⁇ l) was added to elute 45 Ca.
  • mice Male ICR mice (mean body weight 25g) were maintained in a controlled lighting environment (12 h on/ 12 h off) for experiment. Animals received an intraperitoneal injection of 0.3ml of the chemical irritant phenyl-p-quinone (dissolved in saline containing 5% ethanol to be a dose of 4.5mg/kg) and 6 mins later, the number of abdominal constrictions was counted in the subsequent 6 mins period. Animals (10 animals/group) received 0.2ml of test compounds solution in vehicle of ethanol/Tween 80/saline (10/10/80) intraperitoneally 30 min before the injection of phenyl-p-quinone.
  • the compound according to the present invention is useful to preventing and treating of pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.
  • the compound according to the present invention is useful to preventing and treating of acute pain, chronic pain, neuropathic pain, post-operative pain, rheumatic arthrodynia, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, HIV-related neuropathy, neurodegeneration, stroke, neurotic/allergic/inflammatory skin disease, psoriasis, pruritus, prurigo, asthma, chronic obstructive pulmonary disease, urinary incontinence, inflammatory bowel disease, hyperacusis, tinnitus, vestibular hypersensitiveness, and inotropic ischemia.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (20)

  1. Verbindung der Formel (I) oder ein pharmazeutisch akzeptables Salz derselben:
    Figure imgb0153
     worin
    X NHCH2, CR11=CR12, NH, CHR11CHR12 oder C=C ist, worin
    R11 und R12 unabhängig voneinander Wasserstoff, Halogen, C1-C5 Alkyl, C1-C5 Alkoxy, Halo (C1-C5) Alkyl oder Phenyl sind;
    R1 Ethenyl oder Ethinyl ist;
    R2 Wasserstoff, Halogen, Nitro, Cyano, C1-C5 Alkyl, C1-C5 Alkoxy, Halo (C1-C5) alkyl, C2-C5 Alkenyl, C2-C5 Alkinyl, Carboxy, C1-C5 Alkoxycarbonyl, C1-C5 Alkylthio, Phenyl oder Phenyl (C1-C3) alkyl ist,
    wobei jedes Phenyl unsubstituiert oder substituiert sein kann mit einem oder mehreren Substituenten ausgewählt aus Carboxy, C1-C5 Alkyl, Halogen, Nitro, C2-C5 Alkenyl, C1-C5 Alkoxy, Halo (C1-C5) alkyl, C1-C5 Alkylcarbonyl, C1-C5 Alkylthio, C1-C5 Alkylsulfonyl und C1-C5 Alkoxycarbonyl;
    R3 Wasserstoff, C1-C5 Alkyl, C1-C5 Alkoxy oder Halo (C1-C5) alkyl ist;
    R4, R5, R6, R7 und R8 unabhängig voneinander
    Wasserstoff, Carboxy, C1-C5 Alkyl, Nitro, C2-C5 Alkenyl, C1-C5 Alkoxy, C2-C5 Alkinyl, Halo (C1-C5) alkyl, C1-C5 Alkylthio, C1-C5 Alkylsulfonyl, C1-C5 Alkylcarbonyl, C1-C5 Alkoxycarbonyl, Hydroxy, C2-C5 Alkenyloxy, C1-C5 Alkoxy (C1-C5) alkoxy, C1-C5 Alkoxy (C1-C5) alkoxy (C1-C5) alkyl, C1-C3 Alkylpiperazinyl, Piperazinyl (C1-C5) alkoxy, Piperidinyl (C1-C5) alkoxy, C1-C5 Alkoxy (C1-C5) alkylamino, C1-C7 Alkylamino, Morpholinyl, Morpholinyl (C1-C5) alkyloxy, Tetrahydropyranyloxy, Phenyl oder Halogen sind,
    worin Phenyl unsubstituiert oder substituiert sein kann mit einem oder mehreren Substituenten ausgewählt aus Carboxy, C1-C5 Alkyl, Halogen, Nitro, C2-C5 Alkenyl, C1-C5 Alkoxy, Halo (C1-C5) alkyl, C1-C5 Alkylcarbonyl, C1-C5 Alkylthio, C1-C5 Alkylsulfonyl, C1-C5 Alkoxycarbonyl oder Piperidinyloxy unsubstituiert oder substituiert mit C1-C5 Alkoxycarbonyl;
    R9 Methansulfonyl ist; und
    R10 Wasserstoff ist.
  2. Die Verbindung der Formel (I) oder ein pharmazeutisch akzeptables Salz derselben gemäß Anspruch 1, worin
    X NHCH2, CR11=CR12 oder C=C ist, worin
    R11 und R12 unabhängig voneinander Wasserstoff, Halogen, C1-C5 Alkyl oder Phenyl sind; und
    R2 Wasserstoff, Halogen, Nitro, Cyano, C1-C5 Alkyl, C1-C5 Alkoxy, Halo (C1-C5) Alkyl, C2-C5 Alkenyl, C2-C5 Alkinyl, Carboxy, C1-C5 Alkoxycarbonyl, C1-C5 Alkylthio, Phenyl oder Phenyl (C1-C3) alkyl ist, wobei jedes Phenyl unsubstituiert oder substituiert sein kann mit einem oder mehreren Substituenten ausgewählt aus Carboxy, C1-C5 Alkyl, Halogen, Nitro, C2-C5 Alkenyl, C1-C5 Alkoxy, Halo (C1-C5) alkyl, C1-C5 Alkylcarbonyl, C1-C5 Alkylthio, C1-C5 Alkylsulfonyl und C1-C5 Alkoxycarbonyl;
    R3 Wasserstoff, C1-C5 Alkyl, C1-C5 Alkoxy oder Halo (C1-C5) alkyl ist; und
    R4, R5, R6, R7 und R8 unabhängig voneinander
    Wasserstoff, Carboxy, C1-C5 Alkyl, Nitro, C2-C5 Alkenyl, C1-C5 alkoxy, C2-C5 Alkinyl, Halo (C1-C5) alkyl, C1-C5 Alkylthio, C1-C5 Alkylsulfonyl, C1-C5 Alkylcarbonyl, C1-C5 Alkoxycarbonyl, Phenyl oder Halogen sind, worin Phenyl unsubstituiert oder substituiert sein kann mit einem oder mehreren Substituenten ausgewählt aus Carboxy, C1-C5 Alkyl, Halogen, Nitro, C2-C5 Alkenyl, C1-C5 Alkoxy, Halo (C1-C5) alkyl, C1-C5 Alkylcarbonyl, C1-C5 Alkylthio, C1-C5 Alkylsulfonyl und C1-C5 Alkoxycarbonyl.
  3. Die Verbindung gemäß einem der vorangehenden Ansprüche oder ein pharmazeutisch akzeptables Salz derselben, worin
    X NHCH2, CR11=CR12 oder C=C ist, worin
    R11 und R12 unabhängig voneinander Wasserstoff, Halogen, C1-C5 Alkyl oder Phenyl sind;
    R2 Wasserstoff, Fluor, Chlor, Brom, Jod, Nitro, Cyano, Methyl, Ethyl, Propyl, Isopropyl, Butyl, Isobutyl, Methoxy, Ethoxy, Trifluormethyl, Carboxy, Methoxycarbonyl oder Phenyl ist;
    R3 Wasserstoff, Methyl oder Ethyl ist, und
    R4, R5, R6, R7 und R8 unabhängig voneinander
    Wasserstoff, Carboxy, Methyl, Ethyl, Propyl, Isopropyl, t-Butyl, Nitro, Ethenyl, Ethinyl, Methylthio, Trifluormethyl, Methoxycarbonyl oder Halogen sind.
  4. Die Verbindung gemäß einem der vorangehenden Ansprüche oder ein pharmazeutisch akzeptables Salz derselben, worin
    X NHCH2, CH=CH oder C=C ist;
    R2 Wasserstoff, Fluor, Chlor, Brom, Jod, Nitro, Cyano, Methyl, Ethyl, Propyl, Isopropyl, Butyl, Isobutyl, Methoxy, Ethoxy, Trifluormethyl, Carboxy, Methoxycarbonyl oder Phenyl ist;
    R3 Wasserstoff, Methyl oder Ethyl ist;
    R4, R5, R7 und R8 Wasserstoff sind; und
    R6 Isopropyl oder t-Butyl ist.
  5. Die Verbindung gemäß einem der vorangehenden Ansprüche mit Formel (la) oder ein pharmazeutisch akzeptables Salz derselben:
    Figure imgb0154
     worin
    X NHCH2 oder CH=CH ist;
    R2 Wasserstoff, Fluor, Chlor, Brom, Iod, Nitro, Cyano, Methyl, Ethyl, Propyl, Isopropyl, Butyl, Isobutyl, Methoxy, Ethoxy, Trifluormethyl, Carboxy, Methoxycarbonyl oder Phenyl ist;
    R3 Wasserstoff, Methyl oder Ethyl ist;
    R4, R5, R7 und R8 Wasserstoff ist; und
    R6 Isopropyl oder t-Butyl ist.
  6. Die Verbindung oder ein pharmazeutisch akzeptables Salz derselben gemäß Anspruch 1, worin
    X NHCH2, CR11=CR12, NH, CHR11CHR12 oder C≡C ist, worin
    R11 und R12 unabhängig voneinander Wasserstoff, Fluor oder Methyl sind;
    R2 Wasserstoff, Fluor, Chlor, Brom, Iod, Nitro, Cyano, Methyl, Ethyl, Propyl, Isopropyl, Butyl, Isobutyl, Methoxy, Ethoxy, Ethinyl, Ethenyl, Carboxy oder Methoxycarbonyl ist;
    R3 Wasserstoff, Methyl oder Ethyl ist;
    R4, R5, R7 und R8 unabhängig voneinander
    Wasserstoff, Fluor, Carboxy, Methyl, Ethyl, Propyl, Isopropyl, t-Butyl, Nitro, Ethenyl, Ethinyl, Trifluormethyl, Methoxycarbonyl, Halogen, Methoxyethoxy, Methoxyethoxymethyl, Methylpiperazinyl, Methoxyethylamino, Hydroxy, Methoxy, Allyloxy, Isohexylamino, Isobutylammino, Isopropylamino, Morpholinyl, Morpholinylethoxy oder Tetrahydropyranyloxy ist; und
    R6 C3-C5 Alkyl oder Halo (C1-C3) alkyl ist.
  7. Die Verbindung oder ein pharmazeutisch akzeptables Salz derselben gemäß einem der Ansprüche 1 bis 6, worin,
    X NHCH2, CR11=CR12, CHR11CHR12 oder C=C ist, worin
    R11 Wasserstoff oder Methyl und R12 Wasserstoff ist;
    R2 Wasserstoff, Fluor, Methyl oder Chlor ist;
    R3 Wasserstoff oder Methyl ist;
    R4 Wasserstoff, Fluor, Methoxymethoxy, Methoxyethoxy, Methoxypropoxy, Methoxy, Methoxyethylamino, Allyloxy oder Tetrahydropyranyloxy ist;
    R5, R7 und R8 Wasserstoff oder Fluor sind; und
    R6 Isopropyl oder t-Butyl ist.
  8. Die Verbindung gemäß Anspruch 1, worin X CHR11-CHR12 ist.
  9. Die Verbindung gemäß Anspruch 8, worin,
    X CHR11-CHR12 ist;
    R11 und R12 Methyl or Wasserstoff sind;
    R2 Wasserstoff, Fluor, Chlor, Brom, Iod, Nitro, Cyano, Methyl, Ethyl, Propyl, Isopropyl, Butyl, Isobutyl, Methoxy, Ethoxy, Trifluormethyl, Carboxy oder Methoxycarbonyl ist;
    R3 Wasserstoff, Methyl oder Ethyl ist;
    R4, R5, R7 und R8 unabhängig voneinander
    Wasserstoff, Fluor, Carboxy, Methyl, Ethyl, Propyl, Isopropyl, t-Butyl, Nitro, Ethenyl, Ethinyl, Trifluormethyl, Methoxycarbonyl, Halogen, Methoxymethoxy, Methoxyethoxy, Methoxypropoxy, Methoxyethoxymethyl, Methylpiperazinyl, Methoxyethylamino, Hydroxy, Methoxy, Allyloxy, Isohexylamino, Isobutylamino, Isopropylamino, Morpholinyl, Morpholinylethoxy oder Tetrahydropyranyloxy sind; und
    R6 Isopropyl, t-Butyl oder Halo(C1-C3)alkyl ist.
  10. Die Verbindung gemäß einem der Ansprüche 8 oder 9, worin
    R11 Wasserstoff oder Methyl ist;
    R12 Wasserstoff ist;
    R2 Wasserstoff, Fluor, Chlor oder Methyl ist;
    R4 Wasserstoff, Fluor, Methoxymethoxy, Methoxyethoxy, Methoxypropoxy, Methoxy, Methoxyethylamino, Allyloxy oder Tetrahydropyranyloxy ist;
    R5, R7 und R8 Wasserstoff oder Fluor sind; und
    R6 tert-Butyl ist.
  11. Verbindung der Formel (Id), oder ein pharmazeutisch akzeptables Salz derselben, gemäß einem der vorangehenden Ansprüche:
    Figure imgb0155
     worin
    R1, R2, R3, R4, R5, R6, R7, R8 und X die gleiche Bedeutung haben wie in einem der vorangehenden Ansprüche.
  12. Die Verbindung oder ein pharmazeutisch akzeptables Salz derselben gemäß Anspruch 1, worin die Verbindung ausgewählt ist aus der Gruppe bestehend aus
    N-{4-[3-(4-t-Butylbenzyl)ureidomethyl]-2-vinylphenyl}methansulfonamid,
    N-{4-[3-(4-t-Butylbenzyl)ureidomethyl]-2-fluor-6-vinylphenyl}methansulfonamid, N-{4-[3-(4-t-Butylbenzyl)ureidomethyl]-2-ethinyl-6-fluorphenyl} methansulfonamid,
    N-{4-[3-(4-t-Butylbenzyl)ureidomethyl]-5-chlor-2-vinylphenyl}methansulfonamid, N-{4-[3-(4-t-Butylbenzyl)ureidomethyl]-5-chlor-2-ethinylphenyl}-methansulfonamid,
    N-(4-{1-(R)-[3-(4-t-Butylbenzyl)ureido]ethyl}-2-vinylphenyl)methansulfonamid,
    (R)-N-(4-{1-[3-(4-t-Butyl-benzyl)-ureido]-ethyl}-2-fluor-6-vinyl-phenyl)-methansulfonamid,
    N-{4-[3-(4-t-Butyl-benzyl)-ureidomethyl]-2-methyl-6-vinyl-phenyl}-methansulfonamid,
    N-{4-[3-(4-t-Butyl-benzyl)-ureidomethyl]-2-chlor-6-vinyl-phenyl}-methansulfonamid,
    3-(4-t-Butylphenyl)propiolsäure 3-fluor-4-methansulfonylamino-5-vinylbenzylamide,
    3-(4-t-Butylphenyl)propiolsäure [1-(3-fluor-4-methansulfonylamino-5-vinylphenyl)ethyl]amid,
    3-(4-t-Butylphenyl)-N-[1-(R)-(4-methansulfonylamino-3-vinylphenyl)ethyl]-acrylamid,
    3-(4-t-Butylphenyl)-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)acrylamid,
    3-(4-t-Butylphenyl)-N-(3-fluor-5-ethinyl-4-methansulfonyl amino-benzyl)-acrylamid,
    3-(4-t-Butylphenyl)-N-(4-methansulfonylamino-3-vinylbenzyl)acrylamid,
    3-(4-Trifluormethylphenyl)-N-(4-methansulfonylamino-3-vinylbenzyl)acrylamid,
    3-(4-t-Butylphenyl)-N-(3-chlor-4-methansulfonylamino-5-vinylbenzyl)acrylamid,
    3-(4-t-Butyl-2-morpholin-4-yl-phenyl)-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)acrylamid,
    3-(4-t-Butyl-2-methoxyethoxy-phenyl)-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)acrylamid,
    3-[4-t-Butyl-2-(2-methoxyethylamino)phenyl]-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)acrylamid,
    3-(4-t-Butyl-2-methoxyphenyl)-N-(3-fluor-4-methansulfonylamino-5-vinyl-benzyl) acrylamid,
    3-(2-Allyloxy-4-t-butylphenyl)-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl) acrylamide,
    3-[4-t-Butyl-2-(3-methylbutylamino)phenyl]-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)acrylamid,
    3-(4-t-Butyl-2-isopropylaminophenyl)-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)acrylamid,
    3-(4-t-Butylphenyl)-N-[1-(3-fluor-4-methansulfonylamino-5-vinylphenyl)ethyl] propionamid,
    3-(4-t-Butylphenyl)-N-[1-(3-fluor-4-methansulfonylmino-5-vinylphenyl)ethyl] acrylamide,
    3-(4-t-Butylphenyl)-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)-2-methylacrylamid,
    3-(4-t-Butylphenyl)-2-fluor-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl) acrylamid,
    3-[4-t-Butyl-2-(tetrahydropyran-4-yloxy)phenyl]-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)acrylamid,
    3-[4-t-Butyl-2-(tetrahydropyran-4-yloxy)phenyl]-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)propionamid,
    3-(4-t-Butylphenyl)-N-[1-(4-methansulfonylamino-3-vinylphenyl)ethyl]-2-methylacrylamid,
    3-(4-t-Butylphenyl)-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)-2-methylpropionamid,
    3-[4-(tert-Butyl)phenyl]-N-[4-(methansulfonylamino)-3-vinylbenzyl]propionamid,
    3-[4-(tert-Butyl)phenyl]-N-[3-fluor-4-(methansulfonylamino)-5-vinylbenzyl] propionamid,
    3-(4-t-Butyl-phenyl)-N-(3-ethinyl-5-fluor-4-methansulfonylamino-benzyl)-propionamid,
    N-(4-{1-[3-(4-t-Butylphenyl)ureido]ethyl}-2-vinylphenyl)methansulfonamid,
    N-(4-{1-[3-(4-t-Butylphenyl)ureido]ethyl}-2-ethinylphenyl)methansulfonamid, und 4-[3-(4-t-Butylphenyl)ureidomethyl]-2-fluor-6-vinylphenyl}methansulfonamid.
  13. Die Verbindung oder ein pharmazeutisch akzeptables Salz derselben gemäß Anspruch 12, worin die Verbindung ausgewählt ist aus der Gruppe bestehend aus
    (R)-N-(4-{1-[3-(4-t-Butyl-benzyl)-ureido]-ethyl}-2-fluor-6-vinyl-phenyl)-methansulfonamid,
    3-(4-t-Butylphenyl)-N-[1-(R)-(4-methansulfonylamino-3-vinyl-phenyl)ethyl] acrylamid,
    3-(4-t-Butylphenyl)-N-(3-fluor-4-methansulfonylamino-5-vinyl-benzyl) acrylamid,
    3-(4-t-Butylphenyl)-N-(3-fluor-5-ethinyl-4-methansulfonyl amino-benzyl) acrylamid,
    (R)-3-(4-t-Butylphenyl)-N-[1-(3-fluor-4-methansulfonylamino-5-vinylphenyl)ethyl] propionamid,
    3-(4-t-Butylphenyl)-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)-2-methylacrylamid,
    3-[4-t-Butyl-2-(tetrahydropyran-4-yloxy)phenyl]-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)propionamid,
    (R)-3-(4-t-Butylphenyl)-N-[1-(4-methansulfonylamino-3-vinylphenyl)ethyl]-2-methylacrylamid,
    N-{4-[3-(4-t-Butylbenzyl)ureidomethyl]-2-fluor-6-vinylphenyl} methansulfonamid,
    N-{4-[3-(4-t-Butylbenzyl)ureidomethyl]-2-ethinyl-6-fluorphenyl} methansulfonamid, 3-(4-tert-Butylphenyl)propiolsäure 3-fluor-4-methansulfonylamino-5-vinylbenzylamid,
    3-(4-t-Butylphenyl)-N-(4-methansulfonylamino-3-vinylbenzyl)acrylamid,
    3-[4-tert-Butyl-2-(2-methoxy-ethoxy)-phenyl]-N-(3-fluor-4-methansulfonylamino-5-vinyl-benzyl)-acrylamid,
    3-[4-tert-Butyl-2-(2-methoxyethylamino)phenyl]-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)acrylamid,
    3-(4-tert-Butyl-2-methoxyphenyl)-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)acrylamid,
    3-(2-Allyloxy-4-tert-butylphenyl)-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)acrylamid,
    (R)-3-(4-tert-Butylphenyl)-N-[1-(3-fluor-4-methansulfonylamino-5-vinylphenyl) ethyl]acrylamid,
    3-(4-tert-Butylphenyl)-N-(3-fluor-4-methansulfonylamino-5-vinylbenzyl)-2-methylpropionamid,
    3-[4-(tert-Butyl)phenyl]-N-[4-(methansulfonylamino)-3-vinylbenzyl] propionamid,
    N-(4-{1-(R)-[3-(4-t-butylbenzyl)ureido]ethyl}-2-vinylphenyl) methansulfonamid,
    3-[4-(tert-Butyl)phenyl]-N-[3-fluor-4-(methansulfonylamino)-5-vinylbenzyl] propionamid und
    (R)-N-(4-{1-[3-(4-tert-Butylphenyl)ureido]ethyl}-2-vinylphenyl) methansulfonamid.
  14. Die Verbindung gemäß einem der vorangehenden Ansprüche zur Verwendung als Medikament.
  15. Pharmazeutische Zusammensetzung enthaltend als Wirkstoff eine Verbindung oder ein pharmazeutisch akzeptables Salz derselben gemäß einem der Ansprüche 1 bis 13 zusammen mit einem pharmazeutisch akzeptablen Träger.
  16. Die pharmazeutische Zusammensetzung gemäß Anspruch 15 zur Verwendung bei der Behandlung eines Zustands ausgewählt aus Schmerz, entzündlichen Erkrankungen der Gelenke, Harnblasenüberempfindlichkeit einschießlich Harninkontinenz, Magen-Darm-Geschwür, Reizdarmsyndrom (irritable bowel syndrome, IBS), chronisch-entzündlichen Darmerkrankungen (IBD), neurotische/allergische/entzündliche Hauterkrankungen, Psoriasis, Asthma, chronisch obstruktive Lungenerkrankung, Pruritus oder Prurigo.
  17. Die pharmazeutische Zusammensetzung gemäß Anspruch 16, worin der Schmerz ein Krankheitszustand ausgewählt aus Osteoarthritis, rheumatoider Arthritis, Spondylitis ankylosans, diabetischer neuropathischer Schmerz, postoperativer Schmerz, nichtentzündlicher muskuloskeletaler Schmerz (einschließlich Fibromyalgie, myofasziale Schmerzen und Rückenschmerzen), Migräne und anderen Arten von Kopfschmerzen ist oder damit in Verbindung steht.
  18. Die pharmazeutische Zusammensetzung gemäß einem der Ansprüche 15 bis 17, dadurch gekennzeichnet, dass sie zur oralen Verabreichung vorgesehen ist.
  19. Die Verbindung oder ein pharmazeutisch akzeptables Salz derselben gemäß einem der Ansprüche 1 bis 13 zur Verwendung in einem Verfahren zur Vorbeugung oder Behandlung eines Krankheitszustands, der mit anormaler Expression und/oder anormaler Aktivierung eines Vanilloidrezeptors in Verbindung steht, wobei der Krankheitszustand ausgewählt ist aus Schmerz, entzündlichen Erkrankungen der Gelenke, Harnblasenüberempfindlichkeit einschießlich Harninkontinenz, Magen-Darm-Geschwür, Reizdarmsyndrom (irritable bowel syndrome, IBS), chronisch-entzündlichen Darmerkrankungen (IBD), neurotische/allergische/entzündliche Hauterkrankungen, Psoriasis, Asthma, chronisch obstruktive Lungenerkrankung, Pruritus oder Prurigo.
  20. Die Verbindung zur Verwendung gemäß Anspruch 19, worin der Krankheitszustand ein Krankheitszustand ausgewählt aus Osteoarthritis, rheumatoider Arthritis, Spondylitis ankylosans, diabetischer neuropathischer Schmerz, postoperativer Schmerz, nichtentzündlicher muskuloskeletaler Schmerz (einschließlich Fibromyalgie, myofasziale Schmerzen und Rückenschmerzen), Migräne und anderen Arten von Kopfschmerzen ist oder damit in Verbindung steht.
EP06716379.0A 2005-03-19 2006-03-15 Neue verbindungen oder pharmazeutisch unbedenkliche salze davon als vanilloidrezeptorantagonist, und pharmazeutische zusammensetzungen, die diese enthalten Active EP1861357B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20050022986 2005-03-19
US66326905P 2005-03-21 2005-03-21
PCT/KR2006/000929 WO2006101318A1 (en) 2005-03-19 2006-03-15 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same

Publications (3)

Publication Number Publication Date
EP1861357A1 EP1861357A1 (de) 2007-12-05
EP1861357A4 EP1861357A4 (de) 2011-08-31
EP1861357B1 true EP1861357B1 (de) 2013-04-24

Family

ID=37023953

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06716379.0A Active EP1861357B1 (de) 2005-03-19 2006-03-15 Neue verbindungen oder pharmazeutisch unbedenkliche salze davon als vanilloidrezeptorantagonist, und pharmazeutische zusammensetzungen, die diese enthalten
EP06716438A Withdrawn EP1861358A4 (de) 2005-03-19 2006-03-17 Neue verbindungen, isomer davon oder pharmazeutisch unbedenkliche salze davon als vanilloidrezeptorantagonist, und pharmazeutische zusammensetzungen, die diese enthalten

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP06716438A Withdrawn EP1861358A4 (de) 2005-03-19 2006-03-17 Neue verbindungen, isomer davon oder pharmazeutisch unbedenkliche salze davon als vanilloidrezeptorantagonist, und pharmazeutische zusammensetzungen, die diese enthalten

Country Status (14)

Country Link
US (2) US7763657B2 (de)
EP (2) EP1861357B1 (de)
JP (2) JP5159604B2 (de)
KR (2) KR101304981B1 (de)
AR (2) AR056943A1 (de)
AU (2) AU2006225496A1 (de)
BR (2) BRPI0608714A2 (de)
CA (2) CA2601871A1 (de)
EA (2) EA200702020A1 (de)
IL (2) IL185892A0 (de)
MX (2) MX2007011466A (de)
NO (2) NO20075353L (de)
TW (2) TW200716523A (de)
WO (2) WO2006101318A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763657B2 (en) * 2005-03-19 2010-07-27 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
AU2007277519B2 (en) 2006-07-27 2011-12-22 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US20110160279A1 (en) * 2007-08-13 2011-06-30 Board Of Trustees Of Southern Illinois University METHODS FOR TREATMENT AND PREVENTION OF OTOTOXICITY BY siRNA
US8557872B2 (en) 2008-01-28 2013-10-15 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
CA2721815C (en) * 2008-05-07 2014-06-10 Yasunori Tsuzuki Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
JP5438103B2 (ja) 2008-07-02 2014-03-12 アモーレパシフィック コーポレイション バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物
ES2673301T3 (es) * 2010-11-03 2018-06-21 University Of Hawaii Métodos y composiciones para la prevención y el tratamiento de la hipertrofia cardíaca
AR085509A1 (es) 2011-03-09 2013-10-09 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
PT2797416T (pt) 2011-12-28 2017-10-23 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
CN107573275A (zh) * 2012-12-28 2018-01-12 日本脏器制药株式会社 肉桂酰胺衍生物
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
MY180206A (en) 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
DK3102208T3 (da) 2014-02-07 2021-03-08 Global Blood Therapeutics Inc Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6087254A (ja) * 1983-10-19 1985-05-16 Japan Carlit Co Ltd:The 新規尿素化合物及びそれを含有する除草剤
US6476076B1 (en) * 1999-02-22 2002-11-05 Pacific Corporation Vanilloid analogues containing resinferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof
JP2004506714A (ja) * 2000-08-21 2004-03-04 パシフィック　コーポレーション 新規チオ尿素化合物及びこれを含有する薬学的組成物
ATE393141T1 (de) 2000-08-21 2008-05-15 Pacific Corp Neue thiourea-derivate und pharmazeutische zusammensetzungen die diese enthalten
GB0105895D0 (en) * 2001-03-09 2001-04-25 Smithkline Beecham Plc Novel compounds
PL373484A1 (en) 2001-12-10 2005-09-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1506167B1 (de) * 2002-05-08 2007-08-29 Bayer HealthCare AG Hydroxy-tetrahydro-naphtalenylharnstoff-derivate
AU2003251828A1 (en) * 2002-07-12 2004-02-02 Janssen Pharmaceutica N.V. Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor
KR100707123B1 (ko) * 2003-07-02 2007-04-16 그뤼넨탈 게엠베하 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물
BRPI0513286A (pt) * 2004-07-15 2008-05-06 Japan Tobacco Inc compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos
ITMI20042042A1 (it) * 2004-10-26 2005-01-26 Pharmeste Srl Derivati solfonammidici antagonisti del recettore dei vanilloidi trpv1
ATE443056T1 (de) * 2005-03-10 2009-10-15 Pfizer Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen
US7763657B2 (en) 2005-03-19 2010-07-27 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
CA2601873A1 (en) 2006-09-28
TW200716523A (en) 2007-05-01
US7763657B2 (en) 2010-07-27
AR053561A1 (es) 2007-05-09
EA200702021A1 (ru) 2008-02-28
WO2006101318A1 (en) 2006-09-28
EA200702020A1 (ru) 2008-02-28
BRPI0608624A2 (pt) 2010-01-19
BRPI0608714A2 (pt) 2010-01-26
IL185891A0 (en) 2008-02-09
CA2601871A1 (en) 2006-09-28
KR101304981B1 (ko) 2013-09-06
MX2007011205A (es) 2008-02-15
EP1861358A4 (de) 2011-08-31
TW200716522A (en) 2007-05-01
AU2006225434A1 (en) 2006-09-28
AU2006225496A1 (en) 2006-09-28
JP2008538109A (ja) 2008-10-09
KR20080007329A (ko) 2008-01-18
JP5064374B2 (ja) 2012-10-31
EP1861357A4 (de) 2011-08-31
IL185892A0 (en) 2008-02-09
JP5159604B2 (ja) 2013-03-06
US20090105258A1 (en) 2009-04-23
JP2008537547A (ja) 2008-09-18
KR20070114821A (ko) 2007-12-04
WO2006101321A1 (en) 2006-09-28
EP1861358A1 (de) 2007-12-05
NO20075354L (no) 2007-12-18
US7960584B2 (en) 2011-06-14
AR056943A1 (es) 2007-11-07
EP1861357A1 (de) 2007-12-05
MX2007011466A (es) 2008-01-16
KR101304979B1 (ko) 2013-09-06
US20080234383A1 (en) 2008-09-25
NO20075353L (no) 2007-12-18

Similar Documents

Publication Publication Date Title
EP1861357B1 (de) Neue verbindungen oder pharmazeutisch unbedenkliche salze davon als vanilloidrezeptorantagonist, und pharmazeutische zusammensetzungen, die diese enthalten
CN101142174B (zh) 作为香草素受体拮抗剂的新化合物，其异构体或其药用盐；和包含其的药物组合物
US7067553B2 (en) Thiourea compounds and the pharmaceutical compositions containing the same
US7858621B2 (en) Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP1154989B1 (de) Vanilloid-analoge die resiniferatoxin-pharmacophore enthalten als wirksame vanilloid rezeptor agonisten und analgetika, zusammensetzungen und ihre verwendung
KR101619341B1 (ko) 바닐로이드 수용체 길항체로서의 신규 화합물, 이의 이성질체 또는 약제학적으로 허용가능한 염, 및 이를 함유하는 약학 조성물
EP1882687A1 (de) Heterozyklische Verbindungen verwendbar als Vanilloid-Rezeptor-Antagonisten und diese enthaltende pharmazeutische Zusammensetzungen
WO2006098554A1 (en) Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
WO2007120012A1 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2007142426A1 (en) Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
JPWO2005035471A1 (ja) エーテル誘導体
US6872748B2 (en) Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same
EP1857440A1 (de) Verbindungen und deren Isomere oder deren pharmazeutisch unbedenkliche Salzen als Antagonisten des Vanilloidreceptors; deren pharmazeutische Zusammensetzungen
NO164651B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminofenol-derivater.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

A4 Supplementary search report drawn up and despatched

Effective date: 20110728

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 275/24 20060101AFI20110722BHEP

Ipc: C07D 295/155 20060101ALI20110722BHEP

Ipc: C07D 295/088 20060101ALI20110722BHEP

Ipc: C07D 309/12 20060101ALI20110722BHEP

Ipc: C07C 311/08 20060101ALI20110722BHEP

Ipc: C07C 311/11 20060101ALI20110722BHEP

Ipc: C07D 211/46 20060101ALI20110722BHEP

Ipc: A61K 31/17 20060101ALI20110722BHEP

17Q First examination report despatched

Effective date: 20120309

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602006035871

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07C0275240000

Ipc: C07C0323620000

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 323/62 20060101AFI20120625BHEP

Ipc: C07D 295/155 20060101ALI20120625BHEP

Ipc: C07D 309/12 20060101ALI20120625BHEP

Ipc: C07C 311/08 20060101ALI20120625BHEP

Ipc: C07C 275/24 20060101ALI20120625BHEP

Ipc: C07D 211/46 20060101ALI20120625BHEP

Ipc: C07C 311/11 20060101ALI20120625BHEP

Ipc: A61K 31/17 20060101ALI20120625BHEP

Ipc: C07F 7/08 20060101ALI20120625BHEP

Ipc: C07D 295/088 20060101ALI20120625BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KIM, SUN-YOUNG

Inventor name: KIM, JOO HYUN

Inventor name: KIM, SUNG-IL 480-2 HONGJUK-RI

Inventor name: JEONG, YEON SU 118-803, SUNGWON APT.

Inventor name: KOH, HYUN JU 105-406, DUSAN APT.,

Inventor name: MOH, JOO HYUN 314-1, BORA-RI

Inventor name: PARK, HYEUNG-GEUN COLLEGE OF PHARMACY, SEOUL NATIO

Inventor name: LIM, KYUNG MIN 320-1205 SIBUM DAEUN MAEUL POSCO TH

Inventor name: SHIN, SONG SEOK

Inventor name: PARK, YOUNG-HO

Inventor name: PARK, SEOL RIN

Inventor name: LEE, KI-WHA 209-501, SANGNOKSU APT.

Inventor name: KIM, HEE-DOO C/O COLLEGE OF PHARMACY, SOOKMYUNG WO

Inventor name: JANG, MI JUNG

Inventor name: WOO, BYOUNG YOUNG 105-1906, CHAMSOLMAEUL WORLD MER

Inventor name: SUH,YOUNG-GER COLLEGE OF PHARMACY, SEOUL NATIONAL

Inventor name: CHOI, JIN KYU 126-1601, HYUNDAI HOMETOWN APT.

Inventor name: KIM, JIN KWAN 102-606 DAEWOO PRUGIO APT. 951

Inventor name: OH, UH TAEK COLLEGE OF PHARMACY, SEOUL NATIONAL UN

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 608553

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006035871

Country of ref document: DE

Effective date: 20130620

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOHEST AG, CH

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 608553

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130424

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130424

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130725

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130804

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130826

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130724

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140127

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006035871

Country of ref document: DE

Effective date: 20140127

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140315

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060315

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130424

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20221220

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20230109

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20230401

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240105

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240105

Year of fee payment: 19

Ref country code: GB

Payment date: 20240105

Year of fee payment: 19